Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia

John Burnett

Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia

Research output: Contribution to journal › Article

Abstract

Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.

Original language	English
Pages (from-to)	495-499
Journal	IDRUGS
Volume	9
Issue number	7
Publication status	Published - 2006

Fingerprint Dive into the research topics of 'Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia'. Together they form a unique fingerprint.

Cite this

@article{07f628398efe438da8f10045697be4ed,

title = "Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia",

abstract = "Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.",

author = "John Burnett",

year = "2006",

language = "English",

volume = "9",

pages = "495--499",

journal = "IDrugs: the Investigational Drugs Journal",

issn = "1369-7056",

publisher = "Current Drugs Ltd",

number = "7",

}

TY - JOUR

T1 - Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia

AU - Burnett, John

PY - 2006

Y1 - 2006

N2 - Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.

AB - Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.

M3 - Article

VL - 9

SP - 495

EP - 499

JO - IDrugs: the Investigational Drugs Journal

JF - IDrugs: the Investigational Drugs Journal

SN - 1369-7056

IS - 7

ER -